Targeted therapies for gastric cancer: failures and hopes from clinical trials

Maria Apicella; Simona Corso; Silvia Giordano

doi:10.18632/oncotarget.14825

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Targeted therapies for gastric cancer: failures and hopes from clinical trials

Maria Apicella, Simona Corso and Silvia Giordano _

PDF | HTML | How to cite

Oncotarget. 2017; 8:57654-57669. https://doi.org/10.18632/oncotarget.14825

Metrics: PDF 2917 views | HTML 7943 views | ?

Abstract

Maria Apicella1,*, Simona Corso1,* and Silvia Giordano1

1 Department of Oncology, University of Torino, Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Torino, Italy

* These authors have contributed equally to the work

Correspondence to:

Silvia Giordano, email:

Simona Corso, email:

Keywords: gastric cancer clinical trials, targeted therapies, HER2, tyrosine kinase receptors, immunotherapy

Received: November 16, 2016 Accepted: January 17, 2017 Published: January 26, 2017

Abstract

Gastric cancer is the third leading cause of cancer mortality worldwide. As surgery is the only curative treatment strategy and conventional chemotherapy has shown limited efficacy -with a median overall survival of 10 months- new treatments are urgently needed. Trastuzumab and Ramucirumab (targeting HER2 and VEGFR2, respectively) are the only targeted therapies approved so far. Indeed, most Phase III clinical trials evaluating molecular drugs in gastric cancer failed. This review will retrace the relevant clinical trials with molecular therapies performed in gastric cancer patients, discussing the possible reasons for their failure and indicating new perspective for a real improvement of the treatment of this disease.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14825

Publication Alerts

Reviews:

Targeted therapies for gastric cancer: failures and hopes from clinical trials

Abstract